Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
85.33
+0.08 (0.09%)
Jan 2, 2026, 4:00 PM EST - Market closed
Edwards Lifesciences Employees
Edwards Lifesciences had 15,800 employees as of December 31, 2024. The number of employees decreased by 4,000 or -20.20% compared to the previous year.
Employees
15,800
Change (1Y)
-4,000
Growth (1Y)
-20.20%
Revenue / Employee
$372,392
Profits / Employee
$86,576
Market Cap
49.52B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15,800 | -4,000 | -20.20% |
| Dec 31, 2023 | 19,800 | 2,500 | 14.45% |
| Dec 31, 2022 | 17,300 | 1,600 | 10.19% |
| Dec 31, 2021 | 15,700 | 800 | 5.37% |
| Dec 31, 2020 | 14,900 | 1,000 | 7.19% |
| Dec 31, 2019 | 13,900 | 1,100 | 8.59% |
| Dec 31, 2018 | 12,800 | 600 | 4.92% |
| Dec 31, 2017 | 12,200 | 1,100 | 9.91% |
| Dec 31, 2016 | 11,100 | 1,300 | 13.27% |
| Dec 31, 2015 | 9,800 | 700 | 7.69% |
| Dec 31, 2014 | 9,100 | 500 | 5.81% |
| Dec 31, 2013 | 8,600 | 400 | 4.88% |
| Dec 31, 2012 | 8,200 | 400 | 5.13% |
| Dec 31, 2011 | 7,800 | 800 | 11.43% |
| Dec 31, 2010 | 7,000 | 600 | 9.38% |
| Dec 31, 2009 | 6,400 | 200 | 3.23% |
| Dec 31, 2008 | 6,200 | 600 | 10.71% |
| Dec 31, 2007 | 5,600 | 50 | 0.90% |
| Dec 31, 2006 | 5,550 | 150 | 2.78% |
| Dec 31, 2005 | 5,400 | 200 | 3.85% |
| Dec 31, 2004 | 5,200 | 200 | 4.00% |
| Dec 31, 2003 | 5,000 | 0 | - |
| Dec 31, 2002 | 5,000 | 189 | 3.93% |
| Dec 31, 2001 | 4,811 | -289 | -5.67% |
| Dec 31, 2000 | 5,100 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EW News
- 11 days ago - HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 12 days ago - FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy - Business Wire
- 17 days ago - Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 24 days ago - Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript - Seeking Alpha
- 4 weeks ago - Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference - Business Wire
- 6 weeks ago - Artisan Global Discovery Fund: Q3 Delivers Strong Results Amid Trimming And Exits - Seeking Alpha
- 2 months ago - Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease - Business Wire
- 2 months ago - Edwards Lifesciences Corporation (EW) Q3 2025 Earnings Call Transcript - Seeking Alpha